<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541125</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000564089</org_study_id>
    <secondary_id>FFCD-0604</secondary_id>
    <secondary_id>EU-20757</secondary_id>
    <secondary_id>EUDRACT-2007-001772-37</secondary_id>
    <nct_id>NCT00541125</nct_id>
  </id_info>
  <brief_title>G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase II, Multicenter Study Evaluating G-CSF as Primary Prophylaxis for Neutropenia Associated With First-line Chemotherapy Regimen FOLFIRI and Bevacizumab in Patients With Metastatic Colorectal Cancer Who Are Homozygous for UGT1A1*28 Polymorphism, the Promoter of the Gene Encoding for the Enzyme UGT1A1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: G-CSF may prevent or control neutropenia caused by first-line therapy in patients
      with metastatic colorectal cancer.

      PURPOSE: This phase II trial is studying how well G-CSF works in preventing neutropenia
      during first-line treatment with chemotherapy and bevacizumab in patients with metastatic
      colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine if primary prophylaxis comprising filgrastim (G-CSF) makes it possible to
           obtain neutropenia lower than grade 4 or a 30% decrease in fever in patients with
           metastatic colorectal cancer receiving first-line FOLFIRI and bevacizumab and who are
           homozygous for allele UGT1A1*28 (genotype 7/7), a promoter of the gene coding for enzyme
           UGT1A1.

      Secondary

        -  Evaluate the objective response rate at 6 months of treatment with FOLFIRI and
           bevacizumab according to RECIST criteria.

        -  Evaluate the toxicity (excluding neutropenia) of FOLFIRI and bevacizumab according to
           NCI-CTC v. 2.0.

        -  Determine progression-free and overall survival.

        -  Determine the time to treatment failure.

      OUTLINE: This is a multicenter study.

      Patients receive bevacizumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90
      minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1.
      Patients also receive filgrastim (G-CSF) subcutaneously on days 5-11. Treatment repeats every
      2 weeks in the absence of disease progression or unacceptable toxicity.

      After completion of study therapy, patients are followed every 2-3 months for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of neutropenia grade 4 or fever</measure>
    <time_frame>2013</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicities by NCI-CTC v. 2.0</measure>
    <time_frame>2013</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response at 6 months by RECIST</measure>
    <time_frame>2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance (except neutropenia) by NCI-CTC v. 2.0</measure>
    <time_frame>2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>2013</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <arm_group_label>FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Histologically confirmed adenocarcinoma of the colon or rectum

               -  Metastatic disease

               -  Not surgically curable

          -  Homozygous for allele UGT1A1*28, the promoter of the gene coding for UGT1A1 (genotype
             7/7)

          -  Measurable and/or evaluable disease

        Exclusion criteria:

          -  Original tumor not removed

          -  CNS metastases

          -  Secondary localized cerebral tumors

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  WHO performance status 0-2

          -  ANC ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9 g/dL

          -  Creatinine &gt; 1.5 mg/dL

          -  Total bilirubin ≤ 1.5 times normal

          -  Alkaline phosphatase ≤ 2.5 times normal (5 times normal if liver involvement)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients of must use effective contraception

        Exclusion criteria:

          -  Progressive gastroduodenal ulcer, prior hemorrhagic ulcer, or perforation in the past
             6 months

          -  Enteropathy or chronic diarrhea

          -  Chronic inflammatory intestinal disease

          -  Intestinal obstruction

          -  Active cardiac disease including any of the following:

               -  Uncontrolled hypertension

               -  Myocardial infarction in the past 12 months

               -  Serious angina

               -  NYHA class II-IV congestive heart failure

               -  Severe arrhythmia (even if treated)

               -  Peripheral vascular disease ≥ grade 2

          -  Unhealed wound, ulcer, or severe bone fracture

          -  Bleeding disorder or coagulopathy

          -  Severe uncontrolled infection or medical condition

          -  Proteinuria &gt; 500 mg/24 hours

          -  Other malignancy within the past 5 years except basal cell skin cancer or curatively
             treated carcinoma in situ of the cervix

          -  Known dihydropyrimidine dehydrogenase deficiency

          -  Severe traumatic injury within the past 4 weeks

        PRIOR CONCURRENT THERAPY:

        Inclusion criteria:

          -  At least 2 weeks since prior radiotherapy

        Exclusion criteria:

          -  Prior chemotherapy for metastatic disease except adjuvant chemotherapy completed &gt; 6
             months ago

          -  Prior irinotecan hydrochloride or bevacizumab

          -  Major surgery or biopsy within the past 4 weeks

          -  Major surgery planned

          -  Puncture in the past week

          -  Chronic aspirin (&gt; 325 mg/day) or NSAIDs

          -  Concurrent antifungal azoles (e.g., ketoconazole, fluconazole, itraconazole)

          -  Concurrent phenytoin (as in yellow fever vaccine)

          -  Concurrent Hypericum perforatum (St. John's wort)

          -  Oral or parenteral coagulant in the past 10 days and during study therapy

               -  Warfarin allowed provided INR &lt; 1.5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Lecomte, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHRU de Tours - Hopital Trousseau</affiliation>
  </overall_official>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>May 27, 2016</last_update_submitted>
  <last_update_submitted_qc>May 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

